Smith+Nephew raises $700M in bonds to refinance 2030 notes
What's the deal? Smith & NephewDealroom has a profile for this one. Try Dealroom →, the FTSE 100 medical technology firm, has priced $700 million in senior notes carrying a 5.750% coupon and maturing in 2036. After underwriting discounts, net proceeds total $690,928,000. BofA SecuritiesDealroom has a profile for this one. Try Dealroom →, J.P. Morgan Securities, Mizuho SecuritiesDealroom has a profile for this one. Try Dealroom → USA, and SMBC Nikko Securities AmericaDealroom has a profile for this one. Try Dealroom → managed the offering.
Why now? The company is refinancing ahead of a 2030 maturity, using most of the proceeds to fund a tender offer for its outstanding 2.032% Senior Notes due 2030. The new debt carries a much higher coupon, reflecting changes in credit markets since the original notes were issued. Any surplus goes to general corporate purposes.
By the numbers: Smith+Nephew reported annual sales of $6.2 billion in 2025. Founded in Hull in 1856, it employs about 17,000 people across roughly 100 countries, operating through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
What could go wrong? Swapping 2.032% debt for 5.750% notes raises interest expenses. Investors will watch how much of the 2030 tender is subscribed and how the higher coupon weighs on the company's costs.
The signal: The raise ranks among the largest post-IPO debt deals from a UK health company, sitting in the 91st percentile of 67 comparable rounds all-time. It shows large medical technology firms managing balance sheets early, trading cheaper legacy debt for costlier terms to push out maturities in a higher-rate world.
Read more: kalkinemedia.com
Image credit: chillly809
